January 6, 2011
LOS ANGELES, January 6, 2011 – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), is scheduled to present at the J.P. Morgan 29th Annual Healthcare Conference at 2:00 p.m. Pacific Time on Tuesday, January 11, 2011 at the Westin St. Francis in San Francisco, California. Keith Leonard, KYTHERA’s President and CEO, will be presenting on behalf of KYTHERA and is expected to discuss KYTHERA’s corporate strategy and provide updates on the clinical progress of the company’s lead product candidate, ATX-101, a first-in-class injectable drug being studied for the reduction of submental (under chin) fat.
“We look forward to participating in this premier healthcare conference and providing an update to the investment community,” said Keith Leonard. “2010 was a very productive year for us during which time we completed a Phase IIB trial with ATX-101, signed a strategic licensing agreement with Bayer HealthCare’s dermatology business, Intendis, and made significant progress with our research programs.”
KYTHERA’s presentation will be available to view online for seven days in the Newsroom at www.kytherabiopharma.com following the live presentation.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. KYTHERA has an innovative pipeline, with its lead program in adipolysis (ATX-101) projected to start Phase III trials this year. The company also has active research programs in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.